{"protocolSection":{"identificationModule":{"nctId":"NCT01259089","orgStudyIdInfo":{"id":"NU 10L01"},"secondaryIdInfos":[{"id":"STU00038215","type":"OTHER","domain":"Northwestern University IRB"}],"organization":{"fullName":"Northwestern University","class":"OTHER"},"briefTitle":"Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer","officialTitle":"A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With \"Acquired Resistance\" to EGFR Tyrosine Kinase Inhibitors"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-04-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-06-04","type":"ACTUAL"},"completionDateStruct":{"date":"2014-09-29","type":"ACTUAL"},"studyFirstSubmitDate":"2010-12-10","studyFirstSubmitQcDate":"2010-12-10","studyFirstPostDateStruct":{"date":"2010-12-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-10-22","resultsFirstSubmitQcDate":"2018-10-24","resultsFirstPostDateStruct":{"date":"2018-11-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-08-27","lastUpdatePostDateStruct":{"date":"2019-09-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Northwestern University","class":"OTHER"},"collaborators":[{"name":"Robert H. Lurie Cancer Center","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.","detailedDescription":"This is a phase I, dose-escalation study of Hsp90 inhibitor AUY922 followed by a phase II study. Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically."},"conditionsModule":{"conditions":["Adenocarcinoma of the Lung","Non-small Cell Lung Cancer"],"keywords":["Adenocarcinoma of the Lung","Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":38,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","interventionNames":["Drug: erlotinib hydrochloride","Drug: Hsp90 inhibitor AUY922","Other: laboratory biomarker analysis","Procedure: needle biopsy","Genetic: mutation analysis","Other: pharmacological study"]}],"interventions":[{"type":"DRUG","name":"erlotinib hydrochloride","description":"Given orally","armGroupLabels":["Arm I"],"otherNames":["CP-358,774","erlotinib","OSI-774","Tarceva"]},{"type":"DRUG","name":"Hsp90 inhibitor AUY922","description":"Given IV","armGroupLabels":["Arm I"],"otherNames":["AUY922"]},{"type":"OTHER","name":"laboratory biomarker analysis","description":"Correlative studies","armGroupLabels":["Arm I"]},{"type":"PROCEDURE","name":"needle biopsy","description":"Undergo image-guided needle biopsy (correlative studies)","armGroupLabels":["Arm I"],"otherNames":["aspiration biopsy","puncture biopsy"]},{"type":"GENETIC","name":"mutation analysis","description":"Correlative studies","armGroupLabels":["Arm I"]},{"type":"OTHER","name":"pharmacological study","description":"Correlative studies","armGroupLabels":["Arm I"],"otherNames":["pharmacological studies"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I)","description":"To determine the maximally tolerated dose (MTD), and recommended phase II dose of AUY922 when given in combination with erlotinib for patients with acquired resistance to erlotinib. (Phase I)\n\nEscalation of dose will be in a 3+3 design. If no dose limiting toxicities (DLTs) are seen in 3 patients enrolled at that dose level, then dose will be escalated to the next dose level and the next 3 patients will be enrolled at that dose. Alternatively, if 1 DLT is seen in 3 patients at that dose level, 3 more patients will be added at that same dose level. If 1 DLT is seen in 6 patients at that dose level, MTD will be determined to be at that dose. If more than 1 DLT is seen at that dose level, then the prior lower dose level will be the considered the MTD.\n\nDLT is defined as any of the following related to the investigational agent: Death and grade 3 and 4 specific hematological and non-hematological toxicities defined in the protocol.","timeFrame":"During the first 4 weeks of treatment for each patient."},{"measure":"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922","description":"Overall response rate (ORR) will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan or MRI:\n\nComplete response (CR) defined as disappearance of all target lesions. Partial Response (PR), defined as \\>=30% decrease in the sum of the longest diameter of target lesions.\n\nStable Disease (SD) defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.\n\nProgressive Disease (PD) defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions","timeFrame":"At 8 weeks from treatment initiation"}],"secondaryOutcomes":[{"measure":"Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II)","description":"To characterize the toxicity profile for the combination of erlotinib and AUY922.\n\nToxicity data will be collected every week for the first 28 day cycle and then every two weeks during treatment and up to 28 days after the last treatment. Adverse events will be graded according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0). In general adverse events (AEs) will be graded according to the following:\n\nGrade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE","timeFrame":"At weeks 1 through 4 and then every 2 weeks during treatment and 30 days post last treatment for up to 2 years and half years"},{"measure":"Incidence of Reported Adverse Events in Phase I","description":"Adverse events will be collected weekly for the first 28 day cycle and then every two weeks during treatment and up to 28 days after the last treatment. Adverse events will be graded according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0). In general adverse events (AEs) will be graded according to the following:\n\nGrade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE","timeFrame":"At weeks 1 through 4 and then every 2 weeks during treatment and 30 days post last treatment, for up to 2 years and half years"},{"measure":"Progression-free Survival (Phase II)","description":"Median Progression Free Survival (PFS) will be calculated from time of treatment initiation until the first documentation of progressive disease. Patients will be considered to have progressive disease when CT scan or MRI show at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","timeFrame":"From the time of first treatment with AUY922 to disease progression for up to 2 years post treatment"},{"measure":"Overall Survival (Phase II)","description":"Overall survival (OS) is defined as the time from treatment initiation until death due to any cause.","timeFrame":"From the time of first treatment with AUY922 to death, followed up to 2 years post treatment"},{"measure":"Overall Survival Among Patients With Acquired Resistance With T790M Mutations (Phase II)","description":"Overall Survival (OS) will be measured from treatment initiation until death due to any cause for patients with acquired resistance with T790M mutations in the phase II portion of the study.","timeFrame":"From the time of first treatment with AUY922 to death, followed for up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have pathologic evidence of advanced lung adenocarcinoma (stage IIIB or stage IV) confirmed histologically/cytologically at NU, MSKCC, or DFCI and EITHER previous RECIST-defined response (CR or PR) to an EGFR-TKI (erlotinib or gefitinib) or an investigational EGFR TK inhibitor OR a documented mutation in the EGFR gene (G719X, exon 19 deletion, L858R, L861Q)\n* Radiographic progression by RECIST during treatment with erlotinib/gefitinib\n* Received treatment with erlotinib/gefitinib throughout the one month prior to enrollment and at least six months at any time\n* Measurable (RECIST) indicator lesion not previously irradiated\n* Must have undergone a biopsy after the development of acquired resistance\n* Karnofsky Performance Status \\>= 70% OR ECOG/WHO Performance Status 0-1\n* Signed informed consent\n* Effective contraception and negative serum pregnancy test obtained within two weeks prior to the first administration of AUY922 in all pre-menopausal women (ie., last menstrual period =\\< 24 months ago) and women \\< 2 years after onset of menopause; menopause is defined as the time at which fertility ceases, where a woman has had no menstruation for \\> 24 months\n* Total bilirubin =\\< 1.5 x Upper Limit of Normal (ULN)\n* AST/SGOT and ALT/SGPT =\\< 3.0 x ULN, or =\\< 5.0 x ULN if liver metastasis present\n* Absolute neutrophil count (ANC) \\>= 1.5 x10\\^9/L\n* Hemoglobin (Hgb) \\>= 9g/dL\n* Platelets (plts) \\>= 100 x 10\\^9/L\n* Serum creatinine =\\< 1.5 x ULN or 24 hour clearance \\>= 50 mL/min\n\nExclusion Criteria:\n\n* Symptomatic CNS metastases which are symptomatic and /or requiring escalating doses of steroids\n* Prior treatment with any HSP90 inhibitor compounds\n* Conventional chemotherapy, radiation or monoclonal antibodies within 4 weeks (erlotinib/gefitinib therapy within the past 4 weeks IS allowed)\n* Palliative radiation within 2 weeks\n* Unresolved diarrhea \\>= CTCAE grade 2\n* Pregnant or lactating women\n* Women of childbearing potential (WCBP) (i.e. women able to become pregnant) not using double-barrier methods of contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly, or surgically sterile); male patients whose partners are WCBP not using double-barrier methods of contraception\n* Acute or chronic liver or renal disease\n* Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol\n* Major surgery =\\< 2 weeks prior to randomization or who have not recovered from such therapy\n* History (or family history) of long QT syndrome\n* Mean QTc \\>= 450 msec on baseline ECG\n* History of clinically manifested ischemic heart disease =\\< 6 months prior to study start\n* History of heart failure or left ventricular (LV) dysfunction (LVEF =\\< 45%) by MUGA or ECG\n* Clinically significant resting bradycardia (\\< 50 beats per minute)\n* Clinically significant ECG abnormalities including 1 or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemi-block (LAHB); ST segment elevation or depression \\> 1mm, or 2nd (Mobitz II), or 3rd degree AV block\n* History ventricular tachycardia\n* Other clinically significant heart disease including congestive heart failure (New York Heart Association class III/IV) or uncontrolled hypertension (\\> 160/90 despite intensive medical management)\n* Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTcF interval and cannot be switched or discontinued to an alternative drug prior to commencing AUY922\n* Known diagnosis of HIV infection (HIV testing is not mandatory)\n* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention\n* Patients who are receiving warfarin (CoumadinÂ®) will be excluded unless =\\< 2 mg/d, with an INR \\< 1.5\n* Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g. Gilbert's syndrome)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Melissa Johnson","affiliation":"Northwestern University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Memorial Sloan-Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]},"referencesModule":{"references":[{"pmid":"25870087","type":"DERIVED","citation":"Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015 May 20;33(15):1666-73. doi: 10.1200/JCO.2014.59.7328. Epub 2015 Apr 13."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The study opened for accrual on March 28, 2011 with an accrual goal of up to 30 patients in phase I and 25 patients in phase II. 18 patients were enrolled treated in phase I and 19 patients treated in phase II. The study was closed permanently on May 6, 2013.","groups":[{"id":"FG000","title":"Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"FG001","title":"Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"FG002","title":"Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"FG003","title":"Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"FG004","title":"Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"FG005","title":"Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"periods":[{"title":"Reached First Response at 4 Weeks","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"20"}]},{"type":"Started Treatment on Study","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"19"}]},{"type":"Completed 4 Weeks of Treatment","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Patient not treated on study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]}]},{"title":"Confirmed Response at 8 Weeks","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"7"}]}]},{"title":"Continued Treatment After 8 Weeks","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]},{"title":"Survival Follow up for Two Years","milestones":[{"type":"STARTED","comment":"All patients that are treated on study go into follow up once they finish treatment.","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"19"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"19"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"13"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"stopped being followed as study closed","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"38"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"25"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"28"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"37"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"11"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"21"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"38"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I)","description":"To determine the maximally tolerated dose (MTD), and recommended phase II dose of AUY922 when given in combination with erlotinib for patients with acquired resistance to erlotinib. (Phase I)\n\nEscalation of dose will be in a 3+3 design. If no dose limiting toxicities (DLTs) are seen in 3 patients enrolled at that dose level, then dose will be escalated to the next dose level and the next 3 patients will be enrolled at that dose. Alternatively, if 1 DLT is seen in 3 patients at that dose level, 3 more patients will be added at that same dose level. If 1 DLT is seen in 6 patients at that dose level, MTD will be determined to be at that dose. If more than 1 DLT is seen at that dose level, then the prior lower dose level will be the considered the MTD.\n\nDLT is defined as any of the following related to the investigational agent: Death and grade 3 and 4 specific hematological and non-hematological toxicities defined in the protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of DLTs seen","timeFrame":"During the first 4 weeks of treatment for each patient.","groups":[{"id":"OG000","title":"Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"OG001","title":"Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"OG002","title":"Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"OG003","title":"Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"},{"id":"OG004","title":"Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"PRIMARY","title":"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922","description":"Overall response rate (ORR) will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan or MRI:\n\nComplete response (CR) defined as disappearance of all target lesions. Partial Response (PR), defined as \\>=30% decrease in the sum of the longest diameter of target lesions.\n\nStable Disease (SD) defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.\n\nProgressive Disease (PD) defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions","populationDescription":"All patients that were treated at the MTD dose of 70mg/m2 AUG922 IV were evaluable for this outcome measure (This includes patients treated in cohort 5 of phase I and all patients treated in phase II of the study)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At 8 weeks from treatment initiation","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}]},{"type":"SECONDARY","title":"Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II)","description":"To characterize the toxicity profile for the combination of erlotinib and AUY922.\n\nToxicity data will be collected every week for the first 28 day cycle and then every two weeks during treatment and up to 28 days after the last treatment. Adverse events will be graded according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0). In general adverse events (AEs) will be graded according to the following:\n\nGrade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE","populationDescription":"Toxicity collected from all patients treated at the MTD of 70mg/m2 AUY922. 6 patients in phase I and 19 patients in phase II were treated at this dose.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"At weeks 1 through 4 and then every 2 weeks during treatment and 30 days post last treatment for up to 2 years and half years","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]},{"title":"Skin rash","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Hyperglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"Night blindness","categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]},{"title":"Hypoalbuminemia","categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Elevated AST","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Hyponatremia","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Elevated bilirubin","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Elevated ALT","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Myalgias/arthralgias","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Visual complaints","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Elevated APL","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Decreased leukocytes","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Pruritis/dry skin","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Hypocalcemia","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Anemia","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Mucositis","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Decreased lymphocytes","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Decreased platelets","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Hypomagnesemia","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Decreased neutrophils","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]},{"type":"SECONDARY","title":"Incidence of Reported Adverse Events in Phase I","description":"Adverse events will be collected weekly for the first 28 day cycle and then every two weeks during treatment and up to 28 days after the last treatment. Adverse events will be graded according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0). In general adverse events (AEs) will be graded according to the following:\n\nGrade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE","populationDescription":"Most frequent adverse events for patients treated with 25 to 55mg/m2 dose of AUY9222.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"At weeks 1 through 4 and then every 2 weeks during treatment and 30 days post last treatment, for up to 2 years and half years","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Skin rash","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Hyperglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Night blindness","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Hypoalbuminemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Elevated AST","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Hyponatremia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Elevated bilirubin","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Elevated ALT","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Myalgias/arthralgias","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Visual complaints","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Elevated ALP","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased leukocytes","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Pruritis/dry skin","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Hypocalcemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"anemia","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Mucositis","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased lymphocytes","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased platelets","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Hypomagnesemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased neutrophils","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (Phase II)","description":"Median Progression Free Survival (PFS) will be calculated from time of treatment initiation until the first documentation of progressive disease. Patients will be considered to have progressive disease when CT scan or MRI show at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","populationDescription":"25 of the patients were treated at the MTD and were evaluable for progression free survival. Data was collected up until September 30 2014 when study was closed permanently and no further data was collected for patients survival due to IND withdrawal.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the time of first treatment with AUY922 to disease progression for up to 2 years post treatment","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.1","upperLimit":"4.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Phase II)","description":"Overall survival (OS) is defined as the time from treatment initiation until death due to any cause.","populationDescription":"25 of the patients were treated at the MTD and were evaluable for progression free survival. Data was collected up until September 30 2014 when study was closed permanently and no further data was collected for patients survival due to IND withdrawal.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the time of first treatment with AUY922 to death, followed up to 2 years post treatment","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"4.0","upperLimit":"17.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival Among Patients With Acquired Resistance With T790M Mutations (Phase II)","description":"Overall Survival (OS) will be measured from treatment initiation until death due to any cause for patients with acquired resistance with T790M mutations in the phase II portion of the study.","populationDescription":"No data was collected or analyzed for this outcome measure. There is no data to report. IND was withdrawn before the studies anticipated termination date.","reportingStatus":"POSTED","timeFrame":"From the time of first treatment with AUY922 to death, followed for up to 2 years","groups":[{"id":"OG000","title":"Arm I","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events were collected weekly for the first 28 day cycle and then every two weeks up to 2 and half year period.","description":"Only highest grade lab AEs were collected for each patient. All other AEs were collected as defined by clinicaltrials.gov. Phase I+II data collected together as toxicity objectives for the study were looking at AEs in relation to this combination of treatment rather than treatment dose.","eventGroups":[{"id":"EG000","title":"Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG001","title":"Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG003","title":"Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG004","title":"Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":6,"deathsNumAtRisk":6,"seriousNumAffected":2,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG005","title":"Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib","description":"Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and 75mg oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Given orally\n\nHsp90 inhibitor AUY922: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nneedle biopsy: Undergo image-guided needle biopsy (correlative studies)\n\nmutation analysis: Correlative studies\n\npharmacological study: Correlative studies","deathsNumAffected":13,"deathsNumAtRisk":19,"seriousNumAffected":1,"seriousNumAtRisk":19,"otherNumAffected":19,"otherNumAtRisk":19}],"seriousEvents":[{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Patient also experienced anemia","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Lower gastrointestinal hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Patient also experienced diarrhea and anemia","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Ileal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Patient also had seizure due to not being able to take keppa because of nausea and vomiting.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Tumor pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Cognitive disturbance","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":19}]},{"term":"Conduction disorder","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Progressive disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Worsening symptoms included dyspnea and pleural effusion","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Diarrhea with blood","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Chest pain","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Titnnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Corneal ulcer","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Flashing lights","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Floaters","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Night blindness","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":3},{"groupId":"EG004","numAffected":4,"numAtRisk":6},{"groupId":"EG005","numAffected":14,"numAtRisk":19}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":3},{"groupId":"EG001","numAffected":3,"numAtRisk":3},{"groupId":"EG002","numAffected":3,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":3},{"groupId":"EG004","numAffected":5,"numAtRisk":6},{"groupId":"EG005","numAffected":19,"numAtRisk":19}]},{"term":"Gastroesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Hemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":5,"numAtRisk":19}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":3,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":7,"numAtRisk":19}]},{"term":"Rectal hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":8,"numAtRisk":19}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":3},{"groupId":"EG001","numAffected":3,"numAtRisk":3},{"groupId":"EG002","numAffected":3,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":3},{"groupId":"EG004","numAffected":5,"numAtRisk":6},{"groupId":"EG005","numAffected":18,"numAtRisk":19}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Eye Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Mucosal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Papulopustular rash","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":19}]},{"term":"Upper Respiratory Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":4,"numAtRisk":6},{"groupId":"EG005","numAffected":10,"numAtRisk":19}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":9,"numAtRisk":19}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":16,"numAtRisk":19}]},{"term":"Cholesterol high","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Creatinine increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Weight loss","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":8,"numAtRisk":19}]},{"term":"Blood Bilirubin Increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":13,"numAtRisk":19}]},{"term":"Activated Partial Thromboplastin time Prolonged","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"INR Increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Platelet Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Neutrophil Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Serum Amylase Increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":4,"numAtRisk":6},{"groupId":"EG005","numAffected":18,"numAtRisk":19}]},{"term":"Hyperuricemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":5,"numAtRisk":6},{"groupId":"EG005","numAffected":16,"numAtRisk":19}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":6,"numAtRisk":19}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":8,"numAtRisk":19}]},{"term":"Hypomagnesemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":5,"numAtRisk":19}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":14,"numAtRisk":19}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Hypernatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Chest wall pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Flank Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Generalized Muscle Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Joint Range of Motion Decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Muscle Weakness, Left-sided","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Muscle Weakness Lower Limb","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Peripheral Sensory Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":9,"numAtRisk":19}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":3,"numAtRisk":3},{"groupId":"EG002","numAffected":2,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":3},{"groupId":"EG004","numAffected":6,"numAtRisk":6},{"groupId":"EG005","numAffected":16,"numAtRisk":19}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":3},{"groupId":"EG004","numAffected":5,"numAtRisk":6},{"groupId":"EG005","numAffected":12,"numAtRisk":19}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Sore Throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Dry Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Erythema Multiforme","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Rash Acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Rash Maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Menopause","organSystem":"Social circumstances","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Bleeding","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Bleeding gums","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Blood in sputum","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Visual Disturbances","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":3,"numAtRisk":19}]},{"term":"Trichiasis of the eyelid","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Fissures","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":19}]},{"term":"Clostridium Difficile (C Diff)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Decreased Appetite","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Cold intolerance","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Taste changes","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Bruise at port site","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Night Sweats","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Reaction at port site","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Muscle cramps","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":19}]},{"term":"Tremors","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Leg and hip pain/weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":19}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Rash from cut","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Sores in mouth","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"Redness on bottom lip","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]},{"term":"New progressive leptomeningeal disease","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":19}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Data was collected up until September 30 2014 when study was closed permanently and no further data was collected for patients survival due to IND withdrawal."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Clinical Trials Office","organization":"Northwestern University","phone":"312-695-1301"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D000077192","term":"Adenocarcinoma of Lung"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D000230","term":"Adenocarcinoma"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"C528044","term":"5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide"},{"id":"D001707","term":"Biopsy, Needle"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001706","term":"Biopsy"},{"id":"D003581","term":"Cytodiagnosis"},{"id":"D003584","term":"Cytological Techniques"},{"id":"D019411","term":"Clinical Laboratory Techniques"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D013048","term":"Specimen Handling"},{"id":"D003949","term":"Diagnostic Techniques, Surgical"},{"id":"D013514","term":"Surgical Procedures, Operative"},{"id":"D011677","term":"Punctures"},{"id":"D008919","term":"Investigative Techniques"}]}},"hasResults":true}